![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetics, Safety and Efficacy of Maraviroc in Pediatric Patients With R5 HIV
|
|
|
Reported by Jules Levin
CROI 2016 Feb 22-24 Boston
Carlo Giaquinto,1 Muthuhadini Patience Mawela,2 Kulkanya Chokephaibulkit,3 Annie Fang,4 Elna van der Ryst,5 Srinivas Rao Valluri,4 Manoli Vourvahis,4 Rebecca Zhang-Roper,6 Lynn McFadyen,7 Jayvant Heera8 1University of Padova, Padova, Italy; 2Sefako Makgatho Health Sciences University, Pretoria, South Africa; 3Siriraj Hospital, Mahidol University, Bangkok Noi, Bangkok, Thailand; 4Pfizer Inc, New York, NY, USA; 5Pfizer Inc, The Research Network, Sandwich, Kent, UK; 6GlaxoSmithKline, Stockley Park, UK; 7Pfizer Inc, Sandwich, Kent, UK, 8Pfizer Inc, Groton, CT, USA
![CROI1](../images/030816/030816-3/CROI1.gif)
![CROI2](../images/030816/030816-3/CROI2.gif)
![CROI3](../images/030816/030816-3/CROI3.gif)
![CROI4](../images/030816/030816-3/CROI4.gif)
![CROI5](../images/030816/030816-3/CROI5.gif)
![CROI6](../images/030816/030816-3/CROI6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|